Summary of the Case: In, 1967, Professor Graeme Clark of the University of Melbourne in Australia began researching implantable hearing devices. Having grown up in a home with a deaf father, he set out to improve the quality of life for those who could not hear. In 1978, his dream led to a significant breakthrough in audiology as a patient surgically receive a 10-channel implantable devices. The operation went well and the recipient could hear his wife speaking to him after the recovery period. Subsequent implants led Professor Clark to believe that his implants could be improved further. In 1979, Nucleus, a group of companies that manufactured highly specialized medical equipment, became interested in the potential of Dr. Clark’s work being made available to wider community. With the support of both University of Melbourne and the Australian Government, Nucleus a group of companies that manufactured highly medical equipment, became interested in the potential of Dr. Clark’s work being made available to wider community. With the support of both the University of Melbourne and the Australian Government, Nucleus set out to develop a commercially viable implantable device and to carry out a worldwide clinical trial. In 1981, Cochlear was establish as a corporate entity in order to continue its business operation. As Cochlear dedicated its efforts year after year to the further development of implantable hearing devices, this Australian company would literally become synonymous with the devices that the deaf community worldwide would know and refer to as “cochlear implants”
Co’s Vision, Mission, CSR
Our Mission
Clinical teams and recipients embrace Cochlear as their partner in hearing for life. This choice is made out of continuing preference for the benefits provided by Cochlear services and products and for the values resonated by Cochlear people.
Award/Achievement
Cochlear wins